Related Experiment Video
Updated: Jun 10, 2026
09:51
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
Published on: December 4, 2023
Laparoscopic cytoreductive nephrectomy: a three-center retrospective analysis
Christopher Blick1, Simon Bott, Asif Muneer
1Department of Urology, The Churchill Hospital, Oxford, United Kingdom.
Journal of Endourology
|July 27, 2010
Summary
Laparoscopic cytoreductive nephrectomy (LCRN) for metastatic renal cell carcinoma appears safe and feasible. This study in the UK shows low morbidity and good perioperative outcomes, supporting LCRN as a viable option.
Area of Science:
- Urology
- Surgical Oncology
- Nephrology
Background:
- Metastatic renal cell carcinoma (mRCC) carries a poor prognosis.
- Limited effective systemic therapies exist for mRCC.
- Cytoreductive nephrectomy (CRN) may offer survival benefits prior to systemic therapy.
Purpose of the Study:
- To assess the peri- and postoperative safety of laparoscopic cytoreductive nephrectomy (LCRN).
- To evaluate the feasibility of LCRN in the United Kingdom.
- To analyze the initial UK experience with LCRN for mRCC.
Main Methods:
- Retrospective analysis of 25 patients with mRCC.
- LCRN performed across three UK centers over a 4-year period.
- Evaluation of perioperative outcomes, including operative time, blood loss, transfusion rates, and hospital stay.
Main Results:
- Tumor sizes ranged from 3.4 cm to 12 cm.
- Median operative time was 175 minutes (range 89-310 min).
- Median blood loss was 150 mL with a low transfusion rate (3 patients).
- Median postoperative hospital stay was 3 days (range 2.5-11 days).
Conclusions:
- Laparoscopic cytoreductive nephrectomy (LCRN) demonstrates safety and feasibility in the UK.
- LCRN is associated with low morbidity and favorable perioperative outcomes.
- Initial experience suggests LCRN is a viable approach for selected mRCC patients.
